To assess the clinical potential of targeting SARDH in TCR-T-cell therapy, which holds significant promise in cancer treatment [5, 43], we established a cell-derived xenograft model by inoculating MART-1+ A375 cells into NOD. The gene discussed is SARDH; the disease is cancer.